What is Meiogenix?
Meiogenix is a Paris-based biotechnology company, originating as a spin-off from the Institut Curie and the INRA. The company's core mission revolves around the development of state-of-the-art breeding technologies designed to increase the genetic diversity of organisms. By expanding natural biodiversity, Meiogenix aims to contribute to the creation of novel products that can safely address pressing global food challenges, positioning itself as a key innovator in the agricultural and biotech sectors.
How much funding has Meiogenix raised?
Meiogenix has raised a total of $14.3M across 2 funding rounds:
Unspecified
$1.3M
Series A
$13M
Unspecified (2011): $1.3M with participation from Kurma Biofund
Series A (2021): $13M led by Sofinnova Partners, Casdin Capital, Genoa Ventures, Alexandria Venture Investments, and Bpifrance
Key Investors in Meiogenix
Kurma Biofund
Kurma Biofund is a prominent European venture capital firm specializing in the funding of healthcare and biotechnology. They invest across various company maturity stages, focusing on transforming scientific discoveries into advanced medicines and medical devices.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, with a strong focus on healthcare and sustainability. They act as hands-on company builders, partnering with entrepreneurs from seed to later stages to develop transformative innovations.
Genoa Ventures
Genoa Ventures is an investment firm dedicated to early-stage companies at the intersection of biology and technology. They aim to empower category-defining companies that can transform industries and create a healthier, cleaner, and more productive world.
What's next for Meiogenix?
The substantial enterprise-level backing and recent strategic investment indicate a strong market confidence in Meiogenix's innovative approach to biodiversity and food security. This capital infusion is expected to accelerate the company's research and development efforts, potentially leading to the scaling of its breeding technologies and the broader commercialization of its solutions. Meiogenix is poised to further solidify its position in the biotech landscape, driving advancements in sustainable agriculture and genetic innovation.
See full Meiogenix company page
